Page 2 - David Bartel News Today

Treasurer of the State of North Carolina grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,367 shares of the biopharmaceutical company’s stock after buying an […]

BMO Capital Markets upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) from a market perform rating to an outperform rating in a research report sent to investors on Friday, The Fly reports. The brokerage currently has $250.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $200.00. Several other […]

California Public Employees Retirement System raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 270,883 shares of the biopharmaceutical company’s stock after acquiring an additional 1,123 shares during the […]

BMO Capital Markets upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) from a market perform rating to an outperform rating in a research report report published on Friday, The Fly reports. They currently have $250.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $200.00. Other analysts also recently […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.57, Briefing.com reports. The business had revenue of $319.29 million during the quarter, compared to analyst estimates of $312.53 million. Alnylam Pharmaceuticals had […]

State Board of Administration of Florida Retirement System lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 137,032 shares of the biopharmaceutical company’s stock after selling […]

Arizona State Retirement System raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 2.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,974 shares of the biopharmaceutical company’s stock after purchasing an additional 803 shares during the […]

ANTIPODES PARTNERS Ltd purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 118 shares of the biopharmaceutical company’s stock, valued at approximately $28,000. A number of other institutional investors and hedge funds […]

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.97) by $0.57, Briefing.com reports. The firm had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. Alnylam Pharmaceuticals had a negative […]

Parametrica Management Ltd cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 31.4% during the fourth quarter, HoldingsChannel reports. The fund owned 9,500 shares of the biopharmaceutical company’s stock after selling 4,339 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 4.6% of Parametrica Management Ltd’s holdings, making the stock its 8th biggest […]